Regulatory Approvals and Sector Licences for Cross‑border M&A in France (2026)

Regulatory approvals france m&a has moved from a late-stage box-ticking exercise to a first-order deal risk that must be addressed at the letter-of-intent stage. In 2026, the recalibration of merger-control practice and an expanded foreign direct investment (FDI) screening regime mean that more transactions are caught, timelines are longer, and the consequences of mismanaging sector licences can be fatal to a deal. For corporate buyers, sellers, in-house counsel and private equity sponsors, the practical question is no longer simply “do we need antitrust clearance? ” but “which regulators, licences and authorisations stand between signing and closing, and how do we draft around them?

” This practitioner guide maps the French regulatory landscape sector by sector, sets out indicative timelines, and supplies conditions-precedent and risk-allocation drafting solutions deal teams can deploy immediately.

Executive summary and action checklist

Regulated-sector transactions in France rarely fail because of price, they fail because of timing and regulatory execution. The central discipline for managing regulatory approvals france m&a is to treat the regulatory pathway as a parallel workstream that begins before the commercial terms are locked. A buyer that discovers at due diligence that a telecom authorisation, banking licence or marketing authorisation cannot simply be assigned, but must be re-applied for, faces weeks or months of unplanned delay. The checklist below distils the immediate steps for each side of the table.

Quick checklist for buyers

• At LOI stage, identify the target’s regulated activities and the licences, authorisations or concessions underpinning them.
• Map each applicable regulator (telecoms, energy, financial services, defence/FDI, healthcare) and confirm whether a transfer, re-authorisation or notification is required.
• Test whether the transaction triggers the applicable merger-control thresholds and the current FDI screening scope before committing to a timetable.
• Build regulatory conditions precedent, long-stop dates and interim-period covenants into the share or asset purchase agreement.
• Decide the fallback position if approval is refused or conditioned, price adjustment, hold-separate, or walk-away.

Quick checklist for sellers

• Prepare a “regulatory data room” early: copies of every licence, authorisation, concession and the conditions attached to them.
• Confirm whether change-of-control or transfer provisions exist in each licence and whether regulator consent is required.
• Anticipate fit-and-proper or security screening of the buyer and surface likely objections before the market process.
• Negotiate certainty on timing, fixed long-stop dates, obligations on the buyer to pursue approvals diligently, and break arrangements if the buyer’s profile delays clearance.
• Protect against interim-period value leakage while approvals are outstanding.

Why 2026 developments change the playbook, merger control and FDI screening

Two parallel developments make 2026 a pivotal year for regulatory approvals france m&a. First, the merger-control framework administered by the Autorité de la concurrence continues to evolve, affecting which transactions must be notified and how the notification burden falls across different deal sizes. Deal teams should note that, unlike some other EU jurisdictions, French merger-control notification is based primarily on turnover thresholds rather than a general power to call in below-threshold deals, so the Autorité’s current published thresholds must be checked at the planning stage. Second, the FDI screening regime run through the Direction générale du Trésor at the Ministère de l’Économie has continued to broaden the list of sensitive sectors and tighten notification obligations.

Deal teams should consult the current published guidance of both authorities at the planning stage, because the practical effect is that transactions previously treated as “clean” may now require filings, and the cumulative review period can materially extend the time between signing and closing.

Key implications for cross-border buyers

The most significant implication is sequencing. Foreign buyers acquiring French targets in sensitive sectors must now assume that FDI clearance, sector licence transfer and merger control may run concurrently, and that the slowest workstream dictates the closing date. The expanded screening scope has drawn in more technology-adjacent, data-intensive and dual-use businesses, meaning that even acquisitions that are not obviously “defence” transactions may require filing with the French Treasury. The regulator continues to scrutinise control structures, ultimate beneficial ownership and the identity of non-EU investors with particular care; note that investments by investors established in the EU or EEA are assessed under a different (and generally narrower) set of triggers than those by investors from outside the EU/EEA.

A buyer that leaves this assessment until after signing risks either a protracted suspensory period or, in the worst case, an unwinding order or penalties.

How to build regulatory risk into valuation and timing

Regulatory risk should be priced, not merely papered over. The practical effect of the current regime is that longer and less certain clearance periods carry a cost of capital and an execution-risk discount that sophisticated sellers will resist and sophisticated buyers will quantify. Deal teams should model the carrying cost of a longer interim period, the risk of regulator-imposed conditions (such as divestments or behavioural undertakings), and the possibility of refusal. These scenarios then feed directly into the condition-precedent architecture, the long-stop date and any purchase-price mechanics. Treating regulatory approvals france m&a as a financial variable rather than a legal afterthought is the discipline that separates deals that close on time from those that drift.

Which regulators, licences and approvals matter, sector-by-sector checklist

The core of any assessment of regulatory approvals france m&a is identifying precisely which authority can block or delay the transaction, what instrument that authority controls, and whether a change of control triggers a transfer, re-authorisation or mere notification. The following sector-by-sector checklist covers the five industries where sector licences most frequently determine deal outcomes in France: telecoms, energy, financial services, defence and dual-use, and healthcare.

Telecoms, ARCEP and spectrum authorisations

Telecommunications transactions engage the Autorité de régulation des communications électroniques, des postes et de la distribution de la presse (ARCEP). The acquisition of a network operator or electronic communications provider typically touches two distinct instruments: the general authorisation or declaration to operate an electronic communications network and service, and any spectrum usage authorisations, which are managed within the broader radio-frequency framework. The key practitioner point is that spectrum authorisations are not always freely transferable; depending on the band and the conditions attached, a transfer may require regulator approval or re-attribution rather than simple assignment.

Buyers acquiring a telecoms operator should therefore confirm, early in diligence, whether ARCEP’s consent or a notification is required in connection with the change of control, and whether any spectrum licences carry coverage, rollout or spectrum-cap conditions that survive the transaction. ARCEP’s published procedures and guidance (verify indicative timing with the current ARCEP guidance at arcep. fr) are the primary source for the operator authorisation and spectrum transfer requirements. The common harm that triggers scrutiny is any concentration that reduces competition in access, backhaul or spectrum holdings.

Energy, CRE, ASN and the Ministry responsible for energy

Energy transactions can engage several authorities depending on the asset. The Commission de régulation de l’énergie (CRE) is central to electricity and gas, with responsibilities covering grid access, network tariffs and the functioning of the regulated markets. Acquiring an electricity or gas supplier, or an interest in regulated network infrastructure, may engage authorisation or notification requirements, and buyers must check whether supply authorisations and grid-access rights transfer with the business or require separate consent (verify current process with CRE guidance at cre. fr and with the Ministry responsible for energy).

Where the target owns, operates or supplies nuclear facilities, the Autorité de sûreté nucléaire et de radioprotection (ASNR), the authority formed from the merger of the former ASN and IRSN, adds a safety-driven licensing layer: nuclear facilities are licensed on terms specific to the operator, and a change of operator or control over a nuclear installation raises safety and competence questions that the nuclear safety authority alone can resolve. Renewable projects carry their own concession and authorisation considerations. The practical lesson is that “energy” is not a single regulatory track, a renewable portfolio, a gas supplier and a nuclear-adjacent asset each carry a distinct approvals profile, and the nuclear track is typically the longest and least flexible.

Financial services, ACPR, AMF and the ECB

Acquisitions of banks, payment institutions and insurance undertakings engage the Autorité de contrôle prudentiel et de résolution (ACPR), which operates under the auspices of the Banque de France, with the Autorité des marchés financiers (AMF) relevant for investment and market-facing businesses, and the European Central Bank involved for significant credit institutions. The defining feature of financial-services M&A is the qualifying-holding regime: acquiring, increasing or crossing certain ownership thresholds in a regulated institution requires prior authorisation, and the acquirer is subject to a fit-and-proper assessment covering reputation, financial soundness, the integrity of the proposed owners, and the robustness of the post-acquisition business plan. Insurance portfolio transfers carry their own approval mechanics.

Buyers should assume a substantive, documentation-heavy process in which the regulator assesses the acquirer’s suitability as an owner, not merely the transaction’s competitive effect (confirm the applicable thresholds and procedure with ACPR guidance at acpr. banque-france. fr). For a cross-border buyer, the fit-and-proper review is frequently the critical-path item, and private equity structures with complex ownership chains should prepare for detailed scrutiny of ultimate beneficial owners.

Defence, dual-use and FDI screening, French Treasury, Ministry of the Armed Forces and SGDSN

The defence fdi screening france regime is administered through the Direction générale du Trésor, with input from the Ministry of the Armed Forces and the Secrétariat général de la défense et de la sécurité nationale (SGDSN). The regime captures investments in sensitive sectors, defence, dual-use technologies, critical infrastructure, and an expanding set of activities touching national security, data and advanced technology. A foreign investor acquiring control of, or a significant stake in, a target active in a protected sector must file for prior authorisation; closing without clearance exposes the parties to severe consequences, including the possibility of the transaction being unwound and the imposition of financial penalties.

The authorisation process allows the authorities to impose conditions or undertakings, for example, commitments to maintain certain capabilities in France, protect sensitive information, or restrict access to particular technologies. Where the target handles sensitive systems, the cybersecurity requirements overseen by the Agence nationale de la sécurité des systèmes d’information (ANSSI) may also be relevant. Because the sensitive-sector scope has broadened, buyers should screen for FDI exposure even in deals that do not look like defence transactions on their face (verify the current sensitive-sector list, ownership thresholds and procedure at tresor. economie. gouv. fr).

Healthcare and pharmaceuticals, ANSM, HAS and ARS

Healthcare and pharma acquisitions engage the Agence nationale de sécurité du médicament et des produits de santé (ANSM) for medicines and medical devices, the Haute Autorité de santé (HAS) for assessment functions, and regional health agencies (ARS) for certain establishment-level matters. The regulatory instruments that matter most in a transaction are manufacturing and import authorisations, Good Manufacturing Practice (GMP) compliance, and marketing authorisations for medicines and devices.

The key practitioner question is whether marketing authorisations and establishment licences transfer automatically with the acquired entity or require a formal transfer application to ANSM; a share acquisition that leaves the licence-holding entity intact is treated differently from an asset deal that carves out products or sites (confirm the transfer mechanics with ANSM guidance at ansm. sante. fr). Buyers should also verify that the target’s GMP certifications are current and that any pending inspections or compliance matters are disclosed, because post-close remediation can be time-consuming and expensive.

When a licence transfer is mandatory versus when a simple notification suffices

The distinction between a mandatory licence transfer and a simple notification is one of the most consequential interpretive questions in regulatory approvals france m&a, because it determines whether the deal can close on schedule or must wait for a substantive regulator decision. The starting point is deal structure. In a pure share acquisition, the licence-holding entity usually survives unchanged, so the question becomes whether the licence contains a change-of-control provision that triggers consent, notification or re-assessment. In an asset acquisition, the licence rarely travels automatically with the assets; the buyer frequently must apply for a new authorisation or a formal transfer, which is a substantive process rather than a formality.

Practical red flags that typically require a transfer or re-application include: licences expressly conditioned on the identity or ownership of the holder (common in telecoms spectrum, nuclear and defence); authorisations subject to fit-and-proper or security assessment of controllers (financial services and FDI-sensitive sectors); and establishment or site-specific authorisations tied to a legal entity that is being carved out (healthcare and energy). The recommended workflow is a staged flowchart: at LOI, catalogue the licences; during due diligence, read the change-of-control and transfer provisions of each instrument against the deal structure; and before signing, engage the relevant regulator, informally where permitted, to confirm whether consent, transfer or notification applies and to gauge indicative timing.

Where the answer is a substantive transfer or re-authorisation, the licence transfer m&a france analysis must drive the condition-precedent architecture and the long-stop date.

Timelines, closing mechanics and interim measures, sector comparison

The following comparison table gives an at-a-glance view of indicative regulatory timeframes by sector, whether closing can occur before approval, and common accelerants. All timeframes are indicative only and must be verified against current regulator guidance; actual periods depend on deal complexity, completeness of filings and whether conditions are imposed. The regulatory timeline france acquisitions analysis should always be built on the regulator’s current published procedure rather than on general ranges.

The central closing-mechanics question is whether the transaction is subject to a suspensory obligation, meaning closing is legally prohibited until clearance is obtained. FDI screening and the qualifying-holding regime in financial services are suspensory in character, so a split signing-and-closing structure with regulatory conditions precedent is standard. Where closing can occur before approval, buyers should still consider interim measures, hold-separate arrangements, restrictions on integration, and escrow of a portion of the consideration, to manage the risk that a regulator subsequently imposes conditions or refuses consent.

Deal-drafting: conditions precedent, reps and warranties, and mitigation options

Once the regulatory map is clear, the agreement must allocate approval risk precisely. The clause framework below illustrates the drafting architecture; all sample language is illustrative and must be reviewed and tailored by qualified French counsel before use. Sound drafting is what converts a regulatory risk into a managed, time-boxed workstream, and it is where experienced advisers add the most value in regulatory approvals france m&a.

Sample CP: regulator approval clause

A regulatory condition precedent should name each required approval, allocate the obligation to pursue it, set a diligence standard, and fix a long-stop date. Illustrative wording: “Completion is conditional upon (a) receipt of the authorisation of [regulator] in respect of the change of control of the Target, and (b) confirmation that no FDI authorisation is required or, if required, that clearance has been granted. The Buyer shall, at its own cost and with reasonable diligence, make all filings and provide all information reasonably required to obtain the Approvals. If the Approvals are not obtained by the Long-Stop Date, either party may terminate.

” Parties should specify who controls the regulatory strategy and whether the buyer must accept remedies or conditions to secure clearance.

Sample interim measures and hold-separate covenants

Where closing precedes full approval or where integration must be restrained, interim covenants protect value and compliance. Illustrative wording: “During the Interim Period, the Seller shall procure that the Target is operated in the ordinary course consistent with past practice, shall not take any Reserved Matter without the Buyer’s consent (such consent not to be unreasonably withheld), and shall maintain all Licences in good standing. The parties shall operate the Target on a hold-separate basis and shall not integrate any regulated operations until the relevant Approvals are obtained.” These covenants balance the buyer’s interest in protecting the asset against the prohibition on gun-jumping and premature exercise of control.

Reps and warranties, indemnities and escrow

Sector-specific warranties should confirm that all required licences are held, valid and in good standing; that there are no pending regulatory proceedings; and that no fact exists that would reasonably be expected to prevent approval of the transaction. For conditions precedent sector approvals, tailor warranties to each regulator, GMP compliance for ANSM, fit-and-proper disclosures for ACPR, spectrum conditions for ARCEP. Where a residual approval or compliance risk survives closing, a specific indemnity backed by an escrow or holdback gives the buyer a funded remedy without having to re-open the price. Escrow release can be tied to receipt of a post-closing confirmation or the lapse of a defined monitoring period.

Remedies, enforcement and post-close obligations

Securing clearance is not always the end of the regulatory workstream. Many authorisations carry ongoing obligations that bind the new owner from completion. In sectors such as telecoms and energy, licence conditions on coverage, service continuity or network access continue to apply, and a change of control may require the buyer to confirm its continued commitment to those conditions. In financial services, the acquirer’s suitability is a continuing matter, and material subsequent changes to ownership can require fresh notification. Where a transaction closes on the basis of an interim or transitional arrangement, the buyer must complete the re-authorisation or transfer within the window permitted by the regulator.

Non-compliance carries real consequences: in the FDI context, closing without required authorisation can expose the parties to the transaction being unwound and to financial penalties, while sector regulators can suspend or revoke licences for breach of conditions. Post-close regulatory monitoring, a defined owner, a compliance calendar, and documented evidence of condition fulfilment, should be built into the integration plan.

Practical timeline and project plan for deal teams

Regulatory approvals should be project-managed against the overall deal timetable from day one. The model plans below are indicative and should be calibrated to the specific regulators engaged.

• 8–12 week transactions (lighter regulatory load). Suitable where only notifications or non-suspensory approvals apply. Map regulators at LOI, prepare filings in parallel with confirmatory due diligence, and sign with short-form regulatory CPs and a tight long-stop date.
• 12–24 week transactions (one substantive clearance). Typical where a single suspensory approval, such as a financial-services qualifying holding or an FDI authorisation, governs the timetable. Begin pre-notification contact before signing, assemble the fit-and-proper or FDI pack early, and set the long-stop date against the regulator’s indicative review period plus a contingency buffer.
• Over 24 week transactions (multiple or complex clearances). Expected where nuclear safety review, concurrent FDI and sector approvals, or remedies negotiations are in play. Run each regulatory track as a separate workstream with its own owner, sequence filings to avoid dependencies, and negotiate interim governance and escrow to bridge the extended period.

Across every model, the recurring success factor is early regulator engagement and a realistic long-stop date. Deal teams that compress regulatory approvals france m&a into an unrealistic window either miss closing or accept conditions they could have negotiated away with more time.

Next steps and resources

Deal teams planning regulatory approvals france m&a in 2026 should begin with a sector mapping exercise at the LOI stage and build the regulatory workstream into the project plan from the outset. For a broader overview of the French market, see the M&A Lawyers France, Practical Guide 2026. Sector deep dives on ARCEP telecoms approvals and ACPR financial-services acquisitions complement this pillar guide, and a sector approvals checklist and clause pack supports implementation.

Sources

1. Autorité de la concurrence
2. ARCEP (Autorité de régulation des communications électroniques, des postes et de la distribution de la presse)
3. Commission de régulation de l’énergie (CRE)
4. Autorité de contrôle prudentiel et de résolution (ACPR) / Banque de France
5. Direction générale du Trésor, FDI screening (Ministère de l’Économie)
6. ANSM (Agence nationale de sécurité du médicament et des produits de santé)
7. ASNR (Autorité de sûreté nucléaire et de radioprotection)
8. ANSSI (Agence nationale de la sécurité des systèmes d’information)